International Stem Cell Corporation (OTC:ISCO) is making progress in the medical community with its findings.
The company, based in Carlsbad, California, announced today that the results of the Company’s pre-clinical studies in traumatic brain injury (TBI) have been published in Theranostics, a prestigious peer-reviewed medical journal.
The publication demonstrated that the clinical-grade neural stem cells used in our Parkinson’s disease clinical trial, ISC-hpNSC®, significantly improve TBI-associated motor, neurological, and cognitive deficits without any safety issues.
Rodents injected with moderate and high doses of ISC-hpNSC® significantly improved motor function, neurologic function, and cognition compared to the control animals receiving no treatment.
Shares in ISCO gained 7.9 cents, or 5.5%, late Wednesday to $1.53, on volume of 35,000 shares
